Skip to main content

Table 2 Regulatory letters by releasing division/office, 1997–2011

From: Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies

Administration

Clinton 2nd administration

Bush administrations

Obama administration

All

 

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

Total

Prescription Drug Promotion

140

162

108

79

69

27

25

23

29

22

20

21

43

52

30

850

Office of Scientific Investigations

2

4

8

5

11

2

2

3

6

9

10

16

20

15

18

131

Compliance

 

1

 

1

2

12

19

10

 

2

1

 

40

17

 

105

Manufacturing and Product Quality

14

7

5

11

6

1

 

1

3

2

3

4

8

16

17

98

Security, Integrity and Recalls

7

8

1

1

    

4

1

20

3

6

6

2

59

Compliance Risk Management and Surveillance

      

1

        

1

Drugs and Labeling Compliance

1

              

1

Prescription Drug Compliance

  

1

            

1

Manufacturing and Product Quality/Division of Compliance Risk Management and Surveillance

 

1

             

1

Unapproved Drugs and Labeling Compliance

              

1

1

District Offices

94

116

96

98

108

81

58

71

60

81

29

85

60

89

93

1,219

Total

258

299

219

195

196

123

105

108

102

117

83

129

177

195

161

2,467

  1. Note: 1 letter released in 1998 by the OMPQ was coauthored by the Division of Prescription Drug Compliance and Surveillance. The names of the Divisions and Offices changed over time. The most current names are included in the table.